Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
Talaris Therapeutics, Inc. (TALS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2022 | -10,786,000 | 13.66 M | 193.72 M | 185.61 M | |
| 2021 | -18,614,000 | 8.61 M | 251.42 M | 246.51 M | |
| 2020 | 374 K | -17,589,000 | 4.77 M | 152.78 M | 150.75 M |
| 2019 | -38,978,000 | 59.04 M | 41.94 M | 40.79 M |